PROLONG (PRostateOLaparibONcombinationGcc) Study
NCT07674121
·
clinicaltrials.gov ↗
NOT_YET_RECRUITING
Status
75
Enrollment
INDUSTRY
Sponsor class
Conditions
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions
DRUG:
Olaparib and Abiraterone Combination
Sponsor
AstraZeneca